Executive Summary: The project introduces the world’s first implantable electrochemical bio-foundry designed for the autonomous, on-demand synthesis of therapeutic peptides and proteins directly within the patient’s body. By integrating a miniaturized cascaded micro-reactor (10-50 mL) with real-time physiological feedback, this system eliminates the need for external drug reservoirs, cold-chain logistics, and frequent injections. The Solution & Innovation: Traditional implantable pumps are limited by the chemical stability of pre-stored drugs. Our platform synthesizes therapeutics (such as insulin, GLP-1, or specific cytokines) in situ from stable amino acid reservoirs. The device utilizes a closed-loop control system governed by PID and Model Predictive Control algorithms, processing data from an integrated biosensor array that monitors glucose, cytokines (IL-6, TNF-alpha), and C-reactive protein. Key Technical Specifications: Tri-Zone Reactor: Cascaded zones for amino acid activation, peptide bond formation, and precision protein folding. Membrane-Free Purification: An advanced electrophoretic module achieves >99% product purity without the fouling issues common in membrane-based systems. Multi-Layer Safety Architecture: Hardware, firmware, and algorithmic interlocks provide response times as low as <1ms to prevent overproduction or adverse physiological reactions. Wireless Interface: 13.56 MHz wireless power transfer and bidirectional communication for external monitoring and protocol updates. Commercialization & IP Status: This technology targets the $100B+ chronic disease management market. The asset is backed by a robust patent portfolio covering the reactor geometry, control logic, and purification methods. At TRL 4, this IP-NFT is a strategic acquisition for MedTech leaders (e.g., Medtronic, Abbott) and biopharma innovators looking to pioneer the "Pharmacy-on-a-Chip" sector. Lead Researcher: Artem G. Teplov Affiliation: Teplov Electrochemical Research | Caltech Alumni Network Contact: Teplov.a.g@gmail.com